{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:05:52Z","timestamp":1792058752003,"version":"4.4.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,5]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Tyrosine kinase inhibitors efficacy in central nervous system (CNS) disease remains uncertain. Ponatinib was studied for CNS distribution in 16 patients with Philadelphia-positive acute lymphoblastic leukemia. Cerebrospinal fluid concentrations fell below the 40 nM threshold, suggesting suboptimal CNS exposure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024024838","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T19:38:21Z","timestamp":1719344301000},"page":"1127-1130","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1+ acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"144","author":[{"given":"Pierre","family":"Walczak","sequence":"first","affiliation":[{"name":"1Hematology Department, Saint-Louis Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6713-1609","authenticated-orcid":false,"given":"Sofiane","family":"Fodil","sequence":"additional","affiliation":[{"name":"1Hematology Department, Saint-Louis Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"2Universit\u00e9 de Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4833-2763","authenticated-orcid":false,"given":"Nicolas","family":"Vignal","sequence":"additional","affiliation":[{"name":"3Pharmacology Department, Saint-Louis Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Cabannes-Hamy","sequence":"additional","affiliation":[{"name":"4Hematology Department, Centre Hospitalier de Versailles, Versailles, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2091-7927","authenticated-orcid":false,"given":"Nicolas","family":"Boissel","sequence":"additional","affiliation":[{"name":"1Hematology Department, Saint-Louis Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"2Universit\u00e9 de Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Raffoux","sequence":"additional","affiliation":[{"name":"1Hematology Department, Saint-Louis Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"2Universit\u00e9 de Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Cayuela","sequence":"additional","affiliation":[{"name":"5Laboratory of Hematology, University Hospital Saint-Louis, Assistance Publique\u2013H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9741-803X","authenticated-orcid":false,"given":"Lauriane","family":"Goldwirt","sequence":"additional","affiliation":[{"name":"3Pharmacology Department, Saint-Louis Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0965-6615","authenticated-orcid":false,"given":"Etienne","family":"Lenglin\u00e9","sequence":"additional","affiliation":[{"name":"1Hematology Department, Saint-Louis Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2024090515204618400_bib1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood.2022017035","article-title":"How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia","volume":"141","author":"Kopmar","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2024090515204618400_bib2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.2020010438","article-title":"Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation","volume":"138","author":"Tang","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2024090515204618400_bib3","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cncr.10265","article-title":"Central nervous system relapse in adults with acute lymphoblastic leukemia","volume":"94","author":"Surapaneni","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"2024090515204618400_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijrobp.2018.05.067","article-title":"Radiation in central nervous system leukemia: guidelines from the International Lymphoma Radiation Oncology Group","volume":"102","author":"Pinnix","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"19","key":"2024090515204618400_bib5","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2023023568","article-title":"Management of ALL in adults: 2023 ELN recommendations from a European expert panel","volume":"143","author":"G\u00f6kbuget","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2024090515204618400_bib6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbmt.2012.08.021","article-title":"Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study","volume":"19","author":"Tanguy-Schmidt","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2024090515204618400_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2018-08-832105","article-title":"How I treat Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"133","author":"Ravandi","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2024090515204618400_bib8","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"issue":"25","key":"2024090515204618400_bib9","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Fo\u00e0","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2024090515204618400_bib10","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2024090515204618400_bib11","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2018-99-117400","article-title":"Safety and efficacy of blinatumomab in patients with central nervous system (CNS) disease: a single institution experience [abstract]","volume":"132","author":"Alfayez","year":"2018","journal-title":"Blood"},{"issue":"22","key":"2024090515204618400_bib12","first-page":"2306","article-title":"Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: results of Children\u2019s Oncology Group trial AALL0622","volume":"36","author":"Slayton","year":"2018","journal-title":"J\u00a0Clin Orthod"},{"issue":"13","key":"2024090515204618400_bib13","first-page":"4674","article-title":"Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate","volume":"9","author":"Pfeifer","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2024090515204618400_bib14","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1182\/blood-2002-10-3059","article-title":"The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr\/Abl-induced leukemia","volume":"101","author":"Wolff","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2024090515204618400_bib15","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2024090515204618400_bib16","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol"},{"issue":"19","key":"2024090515204618400_bib17","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A\u00a0phase 2 trial of ponatinib in Philadelphia chromosome\u2013positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024090515204618400_bib18","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","article-title":"Combination of hyper-CVAD with\u00a0ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study","volume":"5","author":"Jabbour","year":"2018","journal-title":"Lancet Haematol"},{"issue":"8","key":"2024090515204618400_bib19","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1080\/10428194.2021.1894647","article-title":"Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice","volume":"62","author":"Ravi","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2024090515204618400_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/FTD.0000000000000357","article-title":"Development and validation of\u00a0a simultaneous quantification method of 14 tyrosine kinase inhibitors in\u00a0human plasma using LC-MS\/MS","volume":"39","author":"Huynh","year":"2017","journal-title":"Ther Drug Monit"},{"issue":"5","key":"2024090515204618400_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"22","key":"2024090515204618400_bib22","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome\u2013positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024090515204618400_bib23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/jpet.117.246116","article-title":"Pharmacokinetic assessment of cooperative efflux of the multitargeted kinase inhibitor ponatinib across the blood-brain barrier","volume":"365","author":"Laramy","year":"2018","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"2024090515204618400_bib24","unstructured":"Center for Drug Evaluation and Research\n          . CEDR Pharmacology Review: Iclusig. Accessed 2 January 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203469orig1s000clinpharmr.pdf."},{"issue":"suppl 1","key":"2024090515204618400_bib25","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood-2023-188064","article-title":"Chemotherapy-free combination of blinatumomab and ponatinib in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: updates from a phase II trial [abstract]","volume":"142","author":"Haddad","year":"2023","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/10\/1127\/2240683\/blood_bld-2024-024838-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/10\/1127\/2240683\/blood_bld-2024-024838-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T15:39:09Z","timestamp":1725550749000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/10\/1127\/516720\/Cerebrospinal-fluid-distribution-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,9,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024838","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]}}}